Lisdexamfetamine (Vyvanse) Changes Brain Connectivity & Activation to Treat Binge Eating Disorder (2023 Study)
Binge-eating disorder (BED), characterized by recurrent episodes of overeating without compensatory behaviors, is a significant global health concern. Lisdexamfetamine dimesylate (LDX), the only drug approved for moderate to severe BED, is showing promise not just in reducing episodes but also in altering brain function in ways previously not fully understood. Through a groundbreaking study, researchers …